NOVARTIS: Adakveo, first approved drug for sickle cell disease in the US | BUY | CHF107 vs.108 (+21%)
NOVARTIS - BUY | CHF108 (+21%)Adakveo, first approved drug for sickle cell disease in the US
Adakveo, first targeted medication to be approved for SCD
SCD, not a well-known disease
A higher-than-expected price but heavy discounts anticipated
A CHF1 increase to our FV
Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.